September 25, 2018

Skyla Corporation H.S.P.B.   
$\%$ Feng-Yu Lee, Regulatory Principal Consultant IVDD Regulatory Consultant   
29222 Rancho Viejo Road, Suite 218   
San Juan Capistrano, CA 92675

Re: K173127 Trade/Device Name: skyla Hi Hemoglobin A1c System (skyla Hi Analyzer and skyla Hi Hemoglobin A1c Reagent Kit) Regulation Number: 21 CFR 864.7470 Regulation Name: Glycosylated hemoglobin assay Regulatory Class: Class II Product Code: LCP, JJE Dated: August 10, 2018 Received: August 22, 2018

Dear Feng-Yu Lee:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal

statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice   
(https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn   
(http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

# Kellie B. Kelm -S

Courtney H. Lias, Ph.D.GPS Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

510(k) Number (if known) k173127

Device Name The skyla Hi Hemoglobin A1c System (skyla Hi Analyzer and skyla Hi Hemoglobin A1c Reagent Kit)

# CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”

# Skyla Corporation H.S.P.B

# 510(k) SUMMARY

This summary of $5 1 0 ( \mathrm { k } )$ safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92. The assigned 510(k) number is k173127.

# I. APPLICANT INFORMATION:

Name: Skyla Corporation Hsinchu Science Park Branch Address: 1F, No. 8, Dusing Road, Hsinchu Science Park, Hsinchu 300, Taiwan, R.O.C.   
Phone: $+ 8 8 6 - 3 \ – 5 7 8 7 7 2 2$   
Fax: +886-3-5795393   
Contact: Ian Lee

$\mathrm { c / o }$ IVDD Regulatory Consultant 29222 Rancho Viejo Road, Suite 218 San Juan Capistrano, CA 92675 Contact Person: Feng-Yu Lee Phone Number: 1-949-218-0929 Fax Number: 1-949-218-0928

Date Summary Prepared: September $2 4 ^ { \mathrm { t h } }$ , 2018

# II. DEVICES INFORMATION:

# Trade Name:

The skyla Hi Hemoglobin A1c System (skyla Hi Analyzer and skyla Hi Hemoglobin A1c Reagent Kit)

# Classification name, product code, and regulation number:

<table><tr><td rowspan=1 colspan=1>RegulationDescription</td><td rowspan=1 colspan=1>ProductCode</td><td rowspan=1 colspan=1>DeviceClass</td><td rowspan=1 colspan=1>Regulation</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>Glycosylated HemoglobinAssay</td><td rowspan=1 colspan=1>LCP</td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>21 CFR864.7470</td><td rowspan=1 colspan=1>Hematology,81</td></tr><tr><td rowspan=1 colspan=1>Discrete photometricchemistry analyzer forclinical use</td><td rowspan=1 colspan=1>JJE</td><td rowspan=1 colspan=1>I</td><td rowspan=1 colspan=1>962.2160</td><td rowspan=1 colspan=1>Chemistry,75</td></tr></table>

# Skyla Corporation H.S.P.B

# III. PREDICATE DEVICE

The following table identifies the legally marketed device to which Skyla claims equivalence.

# Identification of Predicate Device

<table><tr><td rowspan=2 colspan=1>Subject Device</td><td rowspan=1 colspan=3>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>Predicate Device</td><td rowspan=1 colspan=1>Manufacturer</td><td rowspan=1 colspan=1>510(k) Number</td></tr><tr><td rowspan=1 colspan=1>skyla Hi HemoglobinAlc System</td><td rowspan=1 colspan=1>Alere Afinion Hba1cand Alere AfinionAS100 Analyzer</td><td rowspan=1 colspan=1>Alere Technologies AS</td><td rowspan=1 colspan=1>K151809</td></tr></table>

# IV. DEVICE DESCRIPTION:

The skyla Hi Analyzer is a portable and compact system, and was designed with skyla Hi Hemoglobin A1c Reagent Kit for on-site quantitative measurement of the percent concentration $( \% )$ of glycated hemoglobin (HbA1c $\%$ ) in human blood.

# V. INDICATIONS FOR USE

The skyla Hi Hemoglobin A1c System, consisting of the skyla Hi Analyzer and skyla Hi Hemoglobin A1c Reagent Kit is an in-vitro diagnostic test for quantitative measurement of the percent concentration $( \% )$ of glycated hemoglobin (HbA1c $\%$ ) in venous and finger-stick capillary whole blood   
The measurement of $\%$ HbA1c is used to monitor long-term glycemic control in persons previously diagnosed with diabetes mellitus.   
This system is intended for clinical laboratory and point-of-care use.   
This test is not for screening or diagnosis of diabetes.

# VI. COMPARISION OF TECHNOLOGY CHARACTERISTICS WITH THEPRIDICATE DEVICE

Below tables outline the technological characteristics of the skyla Hi Hemoglobin A1c System in comparison to the legally marketed predicate devices.

# Skyla Corporation H.S.P.B

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=2 colspan=1>Item</td><td rowspan=1 colspan=1>Candidate Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>skyla HiHemoglobin A1c System</td><td rowspan=1 colspan=1>Alere Afinion Hba1c and AlereAfinion AS100 Analyzer</td></tr><tr><td rowspan=1 colspan=1>k number</td><td rowspan=1 colspan=1>k173127</td><td rowspan=1 colspan=1>k151809</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>The skyla Hi Hemoglobin AlcSystem, consisting of the skyla HiAnalyzer and skyla   HiHemoglobin Alc Reagent Kit isan in-vitro diagnostic test forquantitative measurement of thepercent concentration (%) ofglycated hemoglobin (HbA1c %)in venous and finger-stickcapillary whole bloodThe measurement of % HbA1c isused to monitor long-termglycemic control in personspreviously diagnosed withdiabetes mellitus.This system is intended forclinical laboratory and point-of-care use.This test is not for screening ordiagnosis of diabetes.</td><td rowspan=1 colspan=1>Alere   AfinionT   AS100Analyzer System, consisting ofthe Alere AfinionTM AS100Analyzer or Alere AfinionTMAS100 Analyzer Connect andthe Alere AfinionTM TestCartridges, is for in vitrodiagnostic use only. The AlereAfinionT AS100 AnalyzerConnect comprises of the AlereAfinionTM AS100 Analyzer andthe Alere AfinionTM DataConnectivity Converter.Alere AfinionTM AS100 is acompact multi-assay analyzerfor point-of-care testing. It isdesigned to analyze the AlereAfinionTM Test Cartridges. TheAlere AfinionTM  AnalyzerSystem is easy to use, rapid andgives reliable and accurateresults.Alere AfinionTM HbA1c is an invitro diagnostic test forquantitative determination ofglycated             hemoglobin(hemoglobin Alc, HbA1c) inhuman whole blood.The measure of HbAlc isrecommended as a marker oflong-term metabolic control inpersons with diabetes mellitus.</td></tr><tr><td rowspan=1 colspan=1>Type of test</td><td rowspan=1 colspan=1>Quantitative in-vitro diagnostictest</td><td rowspan=1 colspan=1>Quantitative in-vitro diagnostictest</td></tr><tr><td rowspan=1 colspan=1>Intended users</td><td rowspan=1 colspan=1>Professionals and POC</td><td rowspan=1 colspan=1>Professionals and POC</td></tr><tr><td rowspan=1 colspan=1>Blood sampling</td><td rowspan=1 colspan=1>Standard phlebotomy techniquesfor obtaining venous bloodsamples. Fingerstick by use oflancet.</td><td rowspan=1 colspan=1>Standard phlebotomy techniquesfor obtaining venous bloodsamples. Fingerstick by use oflancet.</td></tr></table>

# Skyla Corporation H.S.P.B

<table><tr><td rowspan=1 colspan=1>Design of samplingdevice</td><td rowspan=1 colspan=1>Collect blood with capillary tubein the reagent pack, and insertingthe sampling device into thecartridge</td><td rowspan=1 colspan=1>Collect blood with capillary tubein the reagent pack, and insertingthe sampling device into thecartridge</td></tr><tr><td rowspan=1 colspan=1>Cartridge barcode</td><td rowspan=1 colspan=1>For cartridge expiration and testlot calibration of HbA1c test</td><td rowspan=1 colspan=1>For cartridge expiration and testlot calibration of HbA1c test</td></tr><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=2 colspan=1>Item</td><td rowspan=1 colspan=1>Candidate Device</td><td rowspan=1 colspan=1>Predicate Device</td></tr><tr><td rowspan=1 colspan=1>skyla HiHemoglobin A1c System</td><td rowspan=1 colspan=1>Alere Afinion Hba1c andAlere Afinion AS100 Analyzer</td></tr><tr><td rowspan=1 colspan=1>Test principle</td><td rowspan=1 colspan=1>Immunoturbidimetric assay</td><td rowspan=1 colspan=1>Boronate affinity assay</td></tr><tr><td rowspan=1 colspan=1>Sampling devicecapillary material</td><td rowspan=1 colspan=1>Glass</td><td rowspan=1 colspan=1>Plastic</td></tr><tr><td rowspan=1 colspan=1>Fill volume of samplingdevice capillary</td><td rowspan=1 colspan=1>0.8 μL</td><td rowspan=1 colspan=1>1.5 μL</td></tr><tr><td rowspan=1 colspan=1>Time to result</td><td rowspan=1 colspan=1>6 minutes</td><td rowspan=1 colspan=1>3 minutes</td></tr><tr><td rowspan=1 colspan=1>Linearity</td><td rowspan=1 colspan=1>4% - 14%</td><td rowspan=1 colspan=1>4% - 15%</td></tr></table>

# VII. Discussion of Non-Clinical Tests Performed for Determination of Substantial Equivalence is as follows:

Verification and validation activities were performed on skyla Hi hemoglobin A1c System to establish performance, functionality, and reliability of the device system. Evaluations included precision, linearity, interference, sample volume and hematocrit. POC precision data were tabulated below:

<table><tr><td rowspan=1 colspan=4></td><td rowspan=1 colspan=2>Repeatability(within run)</td><td rowspan=1 colspan=2>BetweenRun</td><td rowspan=1 colspan=2>BetweenDay</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Site</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Mean(%)</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=4 colspan=1>Patient 1(A15)</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5.04</td><td rowspan=1 colspan=1>0.097</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.032</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.103</td><td rowspan=1 colspan=1>2.0%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5.06</td><td rowspan=1 colspan=1>0.082</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>0.039</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>0.034</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>0.097</td><td rowspan=1 colspan=1>1.9%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5.03</td><td rowspan=1 colspan=1>0.075</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.062</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.097</td><td rowspan=1 colspan=1>1.9%</td></tr><tr><td rowspan=1 colspan=1>Combined</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>5.04</td><td rowspan=1 colspan=1>0.085</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.038</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>0.014</td><td rowspan=1 colspan=1>0.3%</td><td rowspan=1 colspan=1>0.095</td><td rowspan=1 colspan=1>1.9%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5.55</td><td rowspan=1 colspan=1>0.097</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.045</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.107</td><td rowspan=1 colspan=1>1.9%</td></tr></table>

# Skyla Corporation H.S.P.B

<table><tr><td rowspan=3 colspan=1>Patient 2(A12)</td><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5.59</td><td rowspan=1 colspan=1>0.095</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.032</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.100</td><td rowspan=1 colspan=1>1.8%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5.56</td><td rowspan=1 colspan=1>0.100</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.065</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.119</td><td rowspan=1 colspan=1>2.1%</td></tr><tr><td rowspan=1 colspan=1>Combined</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>5.56</td><td rowspan=1 colspan=1>0.097</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.049</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.110</td><td rowspan=1 colspan=1>2.0%</td></tr><tr><td rowspan=4 colspan=1>Patient 3(A20)</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>6.57</td><td rowspan=1 colspan=1>0.105</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>0.062</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>0.057</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>0.134</td><td rowspan=1 colspan=1>2.0%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>6.53</td><td rowspan=1 colspan=1>0.111</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.086</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.141</td><td rowspan=1 colspan=1>2.2%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>6.54</td><td rowspan=1 colspan=1>0.110</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.057</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>0.040</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.130</td><td rowspan=1 colspan=1>2.0%</td></tr><tr><td rowspan=1 colspan=1>Combined</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>6.54</td><td rowspan=1 colspan=1>0.109</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.070</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>0.038</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.135</td><td rowspan=1 colspan=1>2.1%</td></tr><tr><td rowspan=4 colspan=1>Patient 4(A24)</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>7.93</td><td rowspan=1 colspan=1>0.126</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>0.099</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>0.067</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>0.174</td><td rowspan=1 colspan=1>2.2%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>7.95</td><td rowspan=1 colspan=1>0.132</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.112</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>0.112</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>0.207</td><td rowspan=1 colspan=1>2.6%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>7.99</td><td rowspan=1 colspan=1>0.150</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.097</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>0.115</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>0.212</td><td rowspan=1 colspan=1>2.7%</td></tr><tr><td rowspan=1 colspan=1>Combined</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>7.96</td><td rowspan=1 colspan=1>0.137</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.103</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>0.100</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>0.198</td><td rowspan=1 colspan=1>2.5%</td></tr><tr><td rowspan=4 colspan=1>Patient 5(B01-7)</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>12.07</td><td rowspan=1 colspan=1>0.243</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.188</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.308</td><td rowspan=1 colspan=1>2.5%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>12.10</td><td rowspan=1 colspan=1>0.250</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>0.189</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.313</td><td rowspan=1 colspan=1>2.6%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>12.13</td><td rowspan=1 colspan=1>0.212</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.138</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>0.096</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>0.270</td><td rowspan=1 colspan=1>2.2%</td></tr><tr><td rowspan=1 colspan=1>Combined</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>12.10</td><td rowspan=1 colspan=1>0.236</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.173</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.292</td><td rowspan=1 colspan=1>2.4%</td></tr><tr><td rowspan=4 colspan=1>Control 1(Y1)</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5.24</td><td rowspan=1 colspan=1>0.092</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.085</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>0.033</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.130</td><td rowspan=1 colspan=1>2.5%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5.18</td><td rowspan=1 colspan=1>0.115</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.055</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>0.128</td><td rowspan=1 colspan=1>2.5%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>5.20</td><td rowspan=1 colspan=1>0.118</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>0.067</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.136</td><td rowspan=1 colspan=1>2.6%</td></tr><tr><td rowspan=1 colspan=1>Combined</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>5.20</td><td rowspan=1 colspan=1>0.109</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>0.060</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>0.029</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.130</td><td rowspan=1 colspan=1>2.5%</td></tr><tr><td rowspan=2 colspan=1>Contro2</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>9.70</td><td rowspan=1 colspan=1>0.200</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>0.142</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.143</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>0.284</td><td rowspan=1 colspan=1>2.9%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>9.71</td><td rowspan=1 colspan=1>0.208</td><td rowspan=1 colspan=1>2.1%</td><td rowspan=1 colspan=1>0.022</td><td rowspan=1 colspan=1>0.2%</td><td rowspan=1 colspan=1>0.096</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>0.230</td><td rowspan=1 colspan=1>2.4%</td></tr><tr><td rowspan=2 colspan=1>(Y2)</td><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>9.68</td><td rowspan=1 colspan=1>0.228</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.171</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.285</td><td rowspan=1 colspan=1>3.0%</td></tr><tr><td rowspan=1 colspan=1>Combined</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>9.69</td><td rowspan=1 colspan=1>0.213</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>0.052</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>0.140</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>0.260</td><td rowspan=1 colspan=1>2.7%</td></tr><tr><td rowspan=4 colspan=1>Calibrator 1(L5)</td><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>13.59</td><td rowspan=1 colspan=1>0.085</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.100</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.131</td><td rowspan=1 colspan=1>1.0%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>13.57</td><td rowspan=1 colspan=1>0.084</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.132</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.156</td><td rowspan=1 colspan=1>1.2%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>13.60</td><td rowspan=1 colspan=1>0.081</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.094</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.124</td><td rowspan=1 colspan=1>0.9%</td></tr><tr><td rowspan=1 colspan=1>Combined</td><td rowspan=1 colspan=1>240</td><td rowspan=1 colspan=1>13.58</td><td rowspan=1 colspan=1>0.083</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.110</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>0.000</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.138</td><td rowspan=1 colspan=1>1.0%</td></tr></table>

# VIII. Discussion of Clinical Tests Performed:

Method Comparison (POC User Performance Study)

The method comparison study was performed in POC sites by intended operators. It is concluded that either venous whole blood samples or finger-stick capillary samples from candidate device are both comparable to comparative device whole blood testing results.

A total of 243 samples were analyzed. For skyla Hi Hemoglobin A1c System, both venous whole blood sample and finger-stick capillary sample were tested, while for

# Skyla Corporation H.S.P.B

Bio-Rad VARIANT II Hemoglobin testing system, only venous whole blood sample was tested.

Result for POC Methoad Comparison Study:

Regression line for venous whole blood: $\mathbf { y } = 0 . 9 9 4 5 \mathbf { x } + 0 . 0 7 7 9$

Regression line for finger-stick blood: $\mathbf { y } = 0 . 9 9 9 3 \mathbf { x } + 0 . 0 5 8 9$

# IX. CONCULSIONS

The clinical and non-clinical tests performed for skyla Hi Hemoglobin A1c System, demonstrate that the test system is safe, effective and substantially equivalent to the legally marketed device identified above.